Page 4,928«..1020..4,9274,9284,9294,930..4,9404,950..»

Stem-cell therapy 'can be lethal'

Posted: Published on September 6th, 2013

People considering stem-cell treatment have been advised to think again, with six groups of medical specialists issuing a strong warning yesterday that unlicensed stem-cell treatments on offer could kill a patient. The medical societies that issued the statement include the Royal College of Physicians, the Dermatological Society, Heart Association of Thailand under the Royal Patronage of His Majesty the King, the Thai Society of Haematology, the Nephrology Society and the Neurology Society. The statement said the Medical Council of Thailand had only approved the use of stem-cell treatment on blood diseases - namely leukaemia, malignant lymphoma, aplastic anaemia, multiple myeloma and thalassemia. Clinical research on the use of stem-cell treatment is ongoing, but there is no scientific evidence that stem-cell therapy can effectively increasing a person's longevity, or delay organ degeneration or improve a patient's quality of life, Prof Kriang Tungsanga, president of the Royal College of Physicians, said. The move by the medical societies was prompted by widespread ads about stem-cell-based "miracle pills" that claim to ease the symptoms of chronic symptoms such as diabetes and heart disease. The unlicensed use of stem-cell therapy to treat heart disease, diabetes or for aesthetic purposes has become popular among celebrities and … Continue reading

Comments Off on Stem-cell therapy 'can be lethal'

New Way to Track Stem Cell Migration Could Advance Treatments for Brain Tumors and More

Posted: Published on September 6th, 2013

Durham, NC (PRWEB) September 06, 2013 A new study in the current issue of STEM CELLS Translational Medicine shows how a team of scientists led by Rex Moats, Ph.D., and Karen Aboody, M.D., discovered a safe, effective way to track the migration and distribution of neural stem cells used in treating invasive brain tumors. Their method, which involves pre-loading the cells before transplantation with ultra-small, super paramagnetic iron oxide nanoparticles that can then be detected via magnetic resonance imaging (MRI), has been approved for clinical trials in humans and has the potential to greatly accelerate the search for new treatments for deadly brain tumors and other diseases. Numerous stem cell-based therapies are currently under investigation, including an FDA-approved clinical trial focused on employing neural stem cells (NSCs) in delivering drugs targeting invasive brain tumors. The ability to monitor the time course, migration and distribution of stem cells following transplantation into these patients would provide critical information for optimizing treatment regimens, Dr. Moats said. However, no effective cell-tracking methodology had yet garnered clinical acceptance. A labeling and imaging protocol using clinical grade ferumoxytol an iron replacement product currently approved to treat iron deficiency anemia in patients with chronic kidney disease has … Continue reading

Comments Off on New Way to Track Stem Cell Migration Could Advance Treatments for Brain Tumors and More

Novartis signs deal to boost cell therapy portfolio

Posted: Published on September 6th, 2013

Home Mail News Sports Finance Weather Games Groups Answers Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo! News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo! Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? Nightline Fix … Continue reading

Comments Off on Novartis signs deal to boost cell therapy portfolio

America Stem Cell, Inc. Receives FDA Clearance for Its Multi-Center Nationwide Trial

Posted: Published on September 6th, 2013

SAN ANTONIO--(BUSINESS WIRE)-- America Stem Cell, Inc. (ASC) announced today it has received clearance from FDA for its Phase I/IIa nationwide multi-center dual-umbilical cord transplantation study evaluating ASC-101 in patients with hematologic malignancies and myelodysplastic syndrome. ASC-101 is currently undergoing evaluation in a single-center study at The University of Texas MD Anderson Cancer. To date, 12 patients have been enrolled in the study with 9 patients evaluable. On the basis of data obtained in the single-center study, FDA has given approval to proceed with a multi-center trial. Enhancing umbilical cord stem cell engraftment into bone marrow in the dual cord transplant setting will improve clinical outcomes for patients with serious, life-threatening cancers and other disorders for which hematopoietic stem cell transplant is prescribed, said, Dr. Elizabeth Shpall, MD, Medical Director, Cell Therapy Laboratory and Director, Cord Blood Bank at M.D. Anderson Cancer Center and Study Chair on the ASC-101 Phase I/IIa clinical trial. Dr. Shpall has submitted an abstract to the upcoming American Society of Hematology (ASH) meeting in December describing the clinical results to date with ASC-101. There is a significant unmet medical need to improve stem cell engraftment into bone marrow for patients undergoing umbilical cord transplantation, and … Continue reading

Comments Off on America Stem Cell, Inc. Receives FDA Clearance for Its Multi-Center Nationwide Trial

Fisher BioServices Intensifies Commitment for Cell Therapy Companies in Clinical Trials and Approaching …

Posted: Published on September 6th, 2013

Rockville, Maryland (PRWEB) September 05, 2013 Fisher BioServices Inc., a leading provider of biorepository/biobanking and ultra cold chain logistics services, announced that Dan ODonnell, Associate Director of Cell Therapy Logistics, will speak at three upcoming industry conferences. Mr. ODonnell, who is widely known for his expertise on ultra cold chain distribution and regulatory compliance in transporting biologics and cryogenically frozen cell-based therapeutics, has been invited to present at the International Society for Cellular Therapy (ISCT) North America Regional Meeting in Philadelphia, Pennsylvania (September 811), the Stem Cell & Regenerative Medicine USA Congress in Cambridge, Massachusetts (September 30October 1), and the ColdChainIQ 11th Annual GDP & Temperature Management Logistics Global Forum in Chicago, Illinois (September 30October 4). Mr. ODonnell will share his expertise on the challenges of moving high value biologics at ultra cold temperatures from the manufacturer to the patient bedsidein clinical trials as well as in the commercial marketplace. This will include an overview of how product packaging and clinical trial design can complicate logistics, add expense, and limit the number of clinical sites available for conducting phase II and phase III clinical trials. He will use a case study format to illustrate the technical challenges of meeting FDA … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Fisher BioServices Intensifies Commitment for Cell Therapy Companies in Clinical Trials and Approaching …

Grafix® Diabetic Foot Ulcer Clinical Trial Accepted for Presentation at the 2013 Symposium on Advanced Wound Care

Posted: Published on September 6th, 2013

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), announced today that its multi-center, randomized, controlled clinical trial evaluating the safety and effectiveness of Grafix for the treatment of chronic diabetic foot ulcers has been accepted for podium presentation at the upcoming Symposium on Advanced Wound Care (SAWC) in Las Vegas on Friday, September 27, 2013. Dr. Larry Lavery, Principal Investigator and Professor of Plastic Surgery at the University of Texas Southwestern Medical Center, will discuss the primary and secondary endpoints as well as additional key safety data from the trial. In August, Osiris reported that the trial had reached the pre-specified stopping rules for overwhelming efficacy. 62% of patients receiving Grafix achieved complete wound closure compared to only 21% (p The 26th Symposium on Advanced Wound Care Conference is held from September 27th to 29th. The meeting is the largest wound care conference in the country and is the official conference of the Association for the Advancement of Wound Care (AAWC). About the Trial (Protocol 302) Protocol 302 is a single-blind, randomized, controlled multi-center trial evaluating the efficacy and safety of weekly applications of Grafix for the treatment of chronic diabetic foot ulcers. A total of 131 patients were enrolled at … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Grafix® Diabetic Foot Ulcer Clinical Trial Accepted for Presentation at the 2013 Symposium on Advanced Wound Care

Neuronal-like cell differentiation of non-adherent BMSCs

Posted: Published on September 6th, 2013

Public release date: 5-Sep-2013 [ | E-mail | Share ] Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research It is widely believed that bone marrow mesenchymal stem cells are highly adherent fibroblastic cells, defined as colony-forming unit-fibroblasts. Nevertheless, a few reports have shown that the non-adherent bone marrow cells can give rise to colony-forming unit-fibroblasts in vitro, and possess a certain differentiation potential. According to a recent study from Dr. Xiaoming Ben and colleagues, non-adherent bone marrow cell-derived mesenchymal stem cells from C57BL/6J mice cultured using the "pour-off" method developed colony-forming unit-fibroblasts, and could be expanded by supple-mentation with epidermal growth factor. The non-adherent bone marrow cell-derived mesenchymal stem cells exposed to basic fibroblast growth factor/epidermal growth factor/nerve growth factor expressed the neuron specific markers, neurofilament-200 and NeuN, in vitro. Non-adherent bone marrow cell-derived mesenchymal stem cells from -galactosidase transgenic mice were also transplanted into focal ischemic brain (right corpus striatum) of C57BL/6J mice. Cells co-labeled with both -galactosidase and NeuN were seen by double immunohistochemical staining. These findings, published in the Neural Regeneration Research (Vol. 8, No. 22, 2013), suggest that the non-adherent bone marrow cell-derived mesenchymal stem cells could differentiate into neuronal-like cells in vitro and in vivo, … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Neuronal-like cell differentiation of non-adherent BMSCs

Epilepsy risk for men reduced with exercise

Posted: Published on September 5th, 2013

Featured Article Academic Journal Main Category: Epilepsy Also Included In: Sports Medicine / Fitness Article Date: 05 Sep 2013 - 0:00 PDT Current ratings for: Epilepsy risk for men reduced with exercise 5 (1 votes) Young male adults who exercise vigorously could reduce their risk of developing epilepsy later in life, according to a study published online in the journal Neurology. Researchers from Sweden analyzed the fitness of 1.17 million Swedish military servicemen, who were required to carry out cycle tests that measured their cardiovascular fitness when they enlisted for service at the age of 18. The participants were then assessed for the prevalence of epilepsy for an average of 25 years. During this period, 6,796 men were diagnosed with the condition. Epilepsy is a brain disorder that causes recurring seizures as a result of abnormal electrical activity in the brain. According to the Centers for Disease Control and Prevention (CDC), around 2 million people in the US currently suffer from the disease. The findings of this study revealed that young men who had a high level of fitness were 79% less likely to develop epilepsy later in life, compared with young men with low fitness levels. Additionally, compared with … Continue reading

Comments Off on Epilepsy risk for men reduced with exercise

Early Diagnosis and Intervention Greatly Improves Outcomes for a Child with Autism; Teach Me LLC in Dallas, Texas is …

Posted: Published on September 5th, 2013

Carrollton, TX (PRWEB) September 05, 2013 When concerns about a childs development arise and autism is suspected, parents and caregivers turn to experts for help. Many parents contact their school district, their childrens physician or look into therapeutic treatments. The road to success for children at risk for autism is often paved by early diagnosis and treatment. With autism on the rise it is more important than ever to seek help early for those at risk. Teach Me llc in Dallas Texas has recently expanded services in Houston, Tulsa and Denver, Colorado to meet the growing need. Specializing in research based, comprehensive evaluations necessary to make an educational diagnosis, their team of licensed behavioral professionals work to bring each child to their full potential. Autism Spectrum Disorder, ASD, represents a broad range of complex neurodevelopment disorders and although there is no definitive test to confirm a diagnosis, understanding the difference between an educational diagnosis and medical diagnosis of ASD can be helpful to parents navigating resources. An Educational Determination of ASD is made by a multidisciplinary evaluation team, comprised of a variety of educational professionals. Along with parent interviews, comprehensive evaluations are conducted to determine the childs eligibility for special … Continue reading

Comments Off on Early Diagnosis and Intervention Greatly Improves Outcomes for a Child with Autism; Teach Me LLC in Dallas, Texas is …

200,000 Heart Disease, Stroke Deaths Could Be Prevented: CDC

Posted: Published on September 5th, 2013

By Steven Reinberg HealthDay Reporter TUESDAY, Sept. 3 (HealthDay News) -- In 2010, more than 200,000 Americans under 75 died from heart disease and stroke that could have been prevented, health officials said Tuesday. Sadly, more than half of those who died were under 65, according to a new report released by the U.S. Centers for Disease Control and Prevention. "As a doctor, I find it heartbreaking to know that the vast majority of people who are having a heart attack or stroke, under the age of 65 in particular, and dying from it didn't have to have that happen," CDC director Dr. Tom Frieden said during a noon press conference. But progress has been made, Frieden said. "The rate of preventable deaths from heart disease and stroke decreased by nearly 30 percent between 2001 and 2010," he noted. Most of this progress, however, has been made among those older than 65. And while these are the people who have the highest risk, most of preventable deaths happen to people under 65. "In that group progress has been much slower," Frieden said. This dichotomy may be because those 65 and older have Medicare with its access to screening and treatment, … Continue reading

Comments Off on 200,000 Heart Disease, Stroke Deaths Could Be Prevented: CDC

Page 4,928«..1020..4,9274,9284,9294,930..4,9404,950..»